Clinical trial
Interleukin-12 Following Chemotherapy in Treating Patients With Refractory…
NCT00003575 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003575 |
|---|---|
| Title | Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma |
| Official title | A Randomized Pre-Phase II Trial of Interleukin-2, Interleukin-12, or No Additional Therapy Following Response to Ifosfamide/Etoposide Chemotherapy for Refractory HIV-Associated Non-Hodgkin's Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, recombinant interleukin-12, etoposide, ifosfamide |
| Enrollment | 40 |
| Start date | Jan 1, 1999 |
| Primary completion | Apr 1, 2002 |
| First posted | May 20, 2004 |
| Last update posted | Feb 8, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: